Volume 7.10 | Mar 15

Hematopoiesis News 7.10 March 14, 2016
Hematopoiesis News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HN on Twitter
 
TOP STORY
Cellular Protein Plays Important Role in Aggressive Childhood Cancer
Scientists have uncovered how a cellular protein contributes to an aggressive form of leukemia prevalent in young children. They discovered that IGF2BP3 binds to and stabilizes hundreds of leukemia-promoting RNA messages and consequently increases how much protein is made, resulting in an environment that is conducive to leukemia cell growth. [Press release from University of California, Los Angeles discussing online publication in The Journal of Clinical Investigation] Press Release | Full Article
Enter for a chance to win ISSCR 2016 Travel Support Award to San Francisco!
 
PUBLICATIONS (Ranked by impact factor of the journal)
Dietary Restriction Improves Repopulation but Impairs Lymphoid Differentiation Capacity of Hematopoietic Stem Cells in Early Aging
The authors analyzed consequences of adult-onset dietary restriction (DR) on hematopoietic stem cell (HSC) function. DR ameliorated HSC aging phenotypes, such as the increase in number of HSCs and the skewing toward myeloid-biased HSCs during aging. [J Exp Med] Abstract

Inductive Interactions Mediated by Interplay of Asymmetric Signaling Underlie Development of Adult Hematopoietic Stem Cells
Using a combination of ex vivo and in vivo approaches, investigators report that stage-specific reciprocal dorso–ventral inductive interactions and lateral input from the urogenital ridges are required to drive hematopoietic stem cells development in the aorta. [Nat Commun] Full Article | Press Release

Therapeutic Targeting and Rapid Mobilization of Endosteal HSC Using a Small Molecule Integrin Antagonist
Researchers showed targeting α9β14β1 integrins with a single dose of a small molecule antagonist (BOP (N-(benzenesulfonyl)-L-prolyl-L-O-(1-pyrrolidinylcarbonyl)tyrosine)) rapidly mobilizes long-term multi-lineage reconstituting hematopoietic stem cell (HSC). [Nat Commun] Full Article

Frequency and Dynamics of Leukemia-Initiating Cells during Short-Term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients
Researchers described an ex vivo co-culture system in which the frequency of leukemic long-term culture-initiating cell can be used as a reliable read-out of leukemia-initiating cells activity over one week. [Cancer Res] Abstract

Kras Is Required for Adult Hematopoiesis
Scientists demonstrated that Kras is a major regulator of TPO and GM-CSF signaling in specific populations of hematopoietic cells and its function is required for adult hematopoiesis. [Stem Cells] Abstract

An In Vitro Model of Hemogenic Endothelium Commitment and Hematopoietic Production
Researchers designed a stromal line-free controlled culture system utilizing the embryonic pre-somitic mesoderm to obtain large numbers of endothelial cells that subsequently commit into hemogenic endothelium before undergoing endothelial-to-hematopoietic transition. [Development] Abstract

Modulation of Hematopoietic Chemokine Effects In Vitro and In Vivo by DPP4/CD26
Investigators evaluated effects of dipeptidylpeptidase4 (DPP4) inhibition (by Diprotin A) or gene deletion of hematopoietic progenitor cells (HPC) on chemokine inhibition of multi-cytokine stimulated HPCs, and on chemokine enhancing effects on single colony stimulating factors-stimulated HPC proliferation, as well as effects of DPP4-treatment of a number of chemokines. [Stem Cells Dev] Abstract

CLINICAL RESEARCH

Lenalidomide Treatment and Prognostic Markers in Relapsed or Refractory Chronic Lymphocytic Leukemia: Data from the Prospective, Multicenter Phase-II CLL-009 Trial
Efficacy of lenalidomide was investigated in 103 patients with relapsed/refractory chronic lymphocytic leukemia treated on the prospective, multicenter randomized Phase-II CLL-009 trial. [Blood Cancer J] Full Article

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children (<18y) and Young Adults (18-29y) with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis
Scientists retrospectively evaluated outcomes in 449 chronic myeloid leukemia patients with early disease receiving myeloablative hematopoietic cell transplantation (HCT) reported to the CIBMTR. They analyzed various factors affecting outcome specifically the effect of age and pre-HCT tyrosine kinase inhibitor in pediatric patients and young adults with the goal of identifying prognostic factors. [Biol Blood Marrow Transplant] Abstract

UM171 & UM729 - Get the Authentic Small Molecules for Ex Vivo Expansion of Human HSCs
 
REVIEWS
MicroRNAs Mediated Regulation of MAPK Signaling Pathways in Chronic Myeloid Leukemia
The authors discussed the potential role of various miRNAs that are found involved in regulating the proteins cascades of mitogen-activated protein kinase (MAPK) signaling pathway associated with chronic myeloid leukemia. [Oncotarget] Full Article

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

Register for Cord Blood Symposium 2016
 
SCIENCE NEWS
Biothera Pharmaceuticals to Present Its Phase II Cancer Immunotherapy Data
Biothera Pharmaceuticals Inc. presented data on its Phase II cancer immunotherapy Imprime PGG, the company’s first-in-class, systemically administered beta glucan PAMP (pathogen associated molecular patterning molecule). [Press release from Biothera Pharmaceuticals Inc. discussing research presented at the Molecular Medicine Tri-Conference 2016, San Francisco] Press Release

From our sponsor: Isolate human immune cells in as little as 8 minutes with EasySep™ Request a sample.
 
INDUSTRY NEWS
Data and Safety Monitoring Board Recommends Advance of Current DC Vaccine Clinical Trial in AML into Phase II
Medigene AG announced the successful recruitment of the planned patients for Phase I of its current clinical trial of dendritic cell (DC) vaccines in acute myeloid leukemia (AML). [Medigene AG] Press Release

FDA Grants Second Orphan Designation For VAL-083
DelMar Pharmaceuticals, Inc. announced that the FDA Office of Orphan Products Development has granted orphan drug designation for its lead product candidate, VAL-083, in the treatment of medulloblastoma. The investigational drug candidate previously received an orphan designation for glioblastoma in the United States and in Europe. [DelMar Pharmaceuticals, Inc.] Press Release
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 14th International Cord Blood Symposium
June 9-11, 2016
San Francisco, United States

Visit our events page to see a complete list of events in the hematopoiesis community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Research Associate – Blood Stem cell Microenvironment (University of Illinois)

Associate Scientist – Hematopoietic Stem Cell Biology (Editas Medicine)

Research Associate – Hematopoietic Stem Cell Biology (Editas Medicine)

Postdoctoral Fellow Positions – Leukemogenesis (The University of Alabama)

Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital)

Postdoctoral Fellow – Cancer Stem Cell Biology (McGill University Health Center)

Postdoctoral Fellow – Cancer Biology (National University of Singapore)

PhD Position – Leukemogenesis and Treatment Resistance (Institute for Tumor Biology and Experimental Therapy)

Translational Research Scientist – Hematology/Oncology (University of Chicago)

Postdoctoral Associate – Epigenetic Regulation of Normal and Leukemic Stem Cells (Sanford Burnham Prebys Medical Discovery Institute)

Assistant/Associate/Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us